Project Details
| Status | Active |
|---|---|
| Effective start/end date | 11/27/17 → 3/31/26 |
Funding
- Sarah Cannon Research Institute (Prot #ML28897/PRO 02 // Prot #ML28897/PRO 02)
- Genentech, Inc (Prot #ML28897/PRO 02 // Prot #ML28897/PRO 02)
Prot #ML28897/PRO 02: MY PATHWAY: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, And Atezolizumab In Patients Who Have Advanced Solid Tumors With Mutations Or Gene Expression Abn
- Villaflor, Victoria Meucci (PD/PI)
Project: Research project